Zobrazeno 1 - 10
of 1 046
pro vyhledávání: '"Tapan M. Kadia"'
Autor:
Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D. Bledsoe, Naval G. Daver, Elias J. Jabbour, Tapan M. Kadia, Zeev Estrov, Steven M. Kornblau, Michael Andreeff, Nitin Jain, Jorge E. Cortes, Gautam Borthakur, Yesid Alvarado, Mary Ann Richie, Mackenzie H. Dobbins, Selene A. McCrackin, Lingsha Zhou, Sherry A. Pierce, Xuemei Wang, Allison M. Pike, Guillermo Garcia-Manero, Hagop M. Kantarjian, Srdan Verstovsek
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Externí odkaz:
https://doaj.org/article/49d445a4471c47e2b55c6d324dad6bf4
Autor:
Danielle Hammond, Sanam Loghavi, Sa A. Wang, Marina Y. Konopleva, Tapan M. Kadia, Naval G. Daver, Maro Ohanian, Ghayas C. Issa, Yesid Alvarado, Nicholas J. Short, Koji Sasaki, Naveen Pemmaraju, Guillermo Montalban-Bravo, Curtis A. Lachowiez, Abhishek Maiti, Guillermo Garcia-Manero, Elias J. Jabbour, Gautam Borthakur, Farhad Ravandi, Koichi Takahashi, Sherry R. Pierce, Hagop M. Kantarjian, Courtney D. DiNardo
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-4 (2023)
Externí odkaz:
https://doaj.org/article/b7c6599d1ff945fc8f42960c8b15f42e
Autor:
Warren Fiskus, Christopher P. Mill, Christine Birdwell, John A. Davis, Kaberi Das, Steffen Boettcher, Tapan M. Kadia, Courtney D. DiNardo, Koichi Takahashi, Sanam Loghavi, Michael J. Soth, Tim Heffernan, Gerard M. McGeehan, Xinjia Ruan, Xiaoping Su, Christopher R. Vakoc, Naval Daver, Kapil N. Bhalla
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Monotherapy with Menin inhibitor (MI), e.g., SNDX-5613, induces clinical remissions in patients with relapsed/refractory AML harboring MLL1-r or mtNPM1, but most patients either fail to respond or eventually relapse. Utilizing single-cell RN
Externí odkaz:
https://doaj.org/article/ac5251edf70f45ea8914536e1354701b
Publikováno v:
Haematologica, Vol 108, Iss 9 (2023)
The last decade has seen steadfast progress in drug development in acute myeloid leukemia (AML) which has moved progressively towards genomic-based therapy. With these advances, outcomes in AML have improved but remains far from satisfactory. One app
Externí odkaz:
https://doaj.org/article/0d1b98e2579745808fac6ffe21cb4f8b
Autor:
Guillaume Richard-Carpentier, Caitlin R. Rausch, Koji Sasaki, Danielle Hammond, Kiyomi Morita, Koichi Takahashi, Guilin Tang, Rashmi Kanagal-Shamanna, Kapil Bhalla, Courtney D. Dinardo, Gautam Borthakur, Naveen Pemmaraju, Elizabeth J. Shpall, Amin Alousi, Naval G. Daver, Guillermo Garcia-Manero, Marina Y. Konopleva, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia
Publikováno v:
Haematologica, Vol 108, Iss 9 (2023)
Acute myeloid leukemia (AML) with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) has a very poor prognosis. Determinants of clinical outcomes and optimal treatment remain uncertain. We retrospectively reviewed 108 cases of AML with inv(3)/t(3;3) and evaluated cl
Externí odkaz:
https://doaj.org/article/669bea5eeb2740ed9b7b6723c8758904
Autor:
Warren Fiskus, Steffen Boettcher, Naval Daver, Christopher P. Mill, Koji Sasaki, Christine E. Birdwell, John A. Davis, Koichi Takahashi, Tapan M. Kadia, Courtney D. DiNardo, Qi Jin, Yuan Qi, Xiaoping Su, Gerard M. McGeehan, Joseph D. Khoury, Benjamin L. Ebert, Kapil N. Bhalla
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Treatment with Menin inhibitor (MI) disrupts the interaction between Menin and MLL1 or MLL1-fusion protein (FP), inhibits HOXA9/MEIS1, induces differentiation and loss of survival of AML harboring MLL1 re-arrangement (r) and FP, or expressin
Externí odkaz:
https://doaj.org/article/bae406bbb1b54e0e95befd702e938368
Autor:
Nicholas J. Short, Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron, Courtney D. Dinardo, Naval Daver, Marina Konopleva, Gautam Borthakur, Elizabeth J. Shpall, Uday Popat, Richard E. Champlin, Rohtesh Mehta, Gheath Al-Atrash, Betul Oran, Elias Jabbour, Guillermo Garcia-Manero, Ghayas C. Issa, Guillermo Montalban-Bravo, Musa Yilmaz, Abhishek Maiti, Hagop Kantarjian
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-10 (2022)
Abstract Background Treated secondary acute myeloid leukemia (ts-AML)—i.e., AML arising from a previously treated antecedent hematologic disorder—is associated with very poor outcomes. The optimal frontline treatment regimen for these patients is
Externí odkaz:
https://doaj.org/article/98d8349f6793447b88974dcf1c4a8542
Autor:
Warren Fiskus, Taghi Manshouri, Christine Birdwell, Christopher P. Mill, Lucia Masarova, Prithviraj Bose, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Gautam Borthakur, Joseph D. Khoury, Srdan Verstovsek, Kapil N. Bhalla
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 1, Pp 1-5 (2022)
Externí odkaz:
https://doaj.org/article/b94caea015564a40b34fc469839116e9
Autor:
Warren Fiskus, Christopher P. Mill, Behnam Nabet, Dimuthu Perera, Christine Birdwell, Taghi Manshouri, Bernardo Lara, Tapan M. Kadia, Courtney DiNardo, Koichi Takahashi, Naval Daver, Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Steven Kornblau, Gautam Borthakur, Guillermo Montalban-Bravo, Guillermo Garcia Manero, Sunil Sharma, Matthew Stubbs, Xiaoping Su, Michael R. Green, Cristian Coarfa, Srdan Verstovsek, Joseph D. Khoury, Christopher R. Vakoc, Kapil N. Bhalla
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 5, Pp 1-16 (2021)
Abstract There is an unmet need to overcome nongenetic therapy-resistance to improve outcomes in AML, especially post-myeloproliferative neoplasm (MPN) secondary (s) AML. Studies presented describe effects of genetic knockout, degradation or small mo
Externí odkaz:
https://doaj.org/article/45520ecba0484c299486fcf8bcac108d
Autor:
Feng Wang, Kiyomi Morita, Courtney D. DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan, Keyur P. Patel, Kyle J. MacBeth, Bin Wu, Guowen Liu, Mark Frattini, Jairo A. Matthews, Latasha D. Little, Curtis Gumbs, Xingzhi Song, Jianhua Zhang, Erika J. Thompson, Tapan M. Kadia, Guillermo Garcia-Manero, Elias Jabbour, Farhad Ravandi, Kapil N. Bhalla, Marina Konopleva, Hagop M. Kantarjian, P. Andrew Futreal, Koichi Takahashi
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
The regulation of resistance to IDH inhibitors in acute myeloid leukaemia is not completely understood. Here the authors reveal with integrative multi-omics analyses that stemness features are major drivers of primary resistance, while high-risk muta
Externí odkaz:
https://doaj.org/article/af530f137f2d430f8c1dd47dd38789db